Meeting
2021 Gastrointestinal Cancers Symposium
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.
Authors
Shubham Pant
The University of Texas MD Anderson Cancer Center, Houston, TX
Shubham Pant , Michel Ducreux , James J. Harding , Milind M. Javle , Do-Youn Oh , Harpreet Singh Wasan , Allison Fortenberry , Neil C. Josephson , Anthony Mwatha , Kui Wang , Jia Fan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04466891
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS352)
DOI
10.1200/JCO.2021.39.3_suppl.TPS352
Abstract #
TPS352
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
First Author: Funda Meric-Bernstam
Poster
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
First Author: Shubham Pant
Poster
2021 ASCO Annual Meeting
Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers.
First Author: Sunyoung S. Lee
Poster
2021 ASCO Annual Meeting
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
First Author: Kensei Yamaguchi